Skip to main content

Table 2 Schedule of assessments and measurement of outcomes

From: Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease

  1. IMP Investigational Medicinal Product, SPPB Short Performance Physical Battery, MDS-UPDRS Movement Disorder Society-Unified Parkinson’s Disease Rating Scale, NFOGQ New Freezing of Gait Questionnaire, ICON-FES Iconographical Falls Efficacy Scale, ICECAP-O ICEpop CAPability measure for Older people, GDS Geriatric Depression Scale, SAS Starkstein Apathy Scale, MoCA Montreal Cognitive Assessment, CES Carer Experience Scale, SDQ Swallowing Disturbance Questionnaire *ECG as per arrhythmia safety protocol **Completed by carer Face-to-Face appointment at home or at the hospital, Remote appointment using video call, Telephone call, Postal letter